JP2013508417A5 - - Google Patents

Download PDF

Info

Publication number
JP2013508417A5
JP2013508417A5 JP2012535441A JP2012535441A JP2013508417A5 JP 2013508417 A5 JP2013508417 A5 JP 2013508417A5 JP 2012535441 A JP2012535441 A JP 2012535441A JP 2012535441 A JP2012535441 A JP 2012535441A JP 2013508417 A5 JP2013508417 A5 JP 2013508417A5
Authority
JP
Japan
Prior art keywords
carbons
composition
alkyl
compound
group containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012535441A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013508417A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/053916 external-priority patent/WO2011050353A1/en
Publication of JP2013508417A publication Critical patent/JP2013508417A/ja
Publication of JP2013508417A5 publication Critical patent/JP2013508417A5/ja
Pending legal-status Critical Current

Links

JP2012535441A 2009-10-23 2010-10-25 アンドロゲン受容体陽性癌を処置する方法 Pending JP2013508417A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25439509P 2009-10-23 2009-10-23
US61/254,395 2009-10-23
PCT/US2010/053916 WO2011050353A1 (en) 2009-10-23 2010-10-25 Method for treating androgen receptor positive cancers

Publications (2)

Publication Number Publication Date
JP2013508417A JP2013508417A (ja) 2013-03-07
JP2013508417A5 true JP2013508417A5 (US20080242721A1-20081002-C00053.png) 2013-12-05

Family

ID=43900720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012535441A Pending JP2013508417A (ja) 2009-10-23 2010-10-25 アンドロゲン受容体陽性癌を処置する方法

Country Status (15)

Country Link
US (1) US8835447B2 (US20080242721A1-20081002-C00053.png)
EP (1) EP2490531A4 (US20080242721A1-20081002-C00053.png)
JP (1) JP2013508417A (US20080242721A1-20081002-C00053.png)
KR (1) KR20120095402A (US20080242721A1-20081002-C00053.png)
CN (1) CN102573472A (US20080242721A1-20081002-C00053.png)
AP (1) AP2012006277A0 (US20080242721A1-20081002-C00053.png)
AU (1) AU2010310477A1 (US20080242721A1-20081002-C00053.png)
BR (1) BR112012009262A2 (US20080242721A1-20081002-C00053.png)
CA (1) CA2779309A1 (US20080242721A1-20081002-C00053.png)
EA (1) EA201290208A1 (US20080242721A1-20081002-C00053.png)
GE (1) GEP20146138B (US20080242721A1-20081002-C00053.png)
IL (1) IL219331A0 (US20080242721A1-20081002-C00053.png)
MX (1) MX2012004624A (US20080242721A1-20081002-C00053.png)
WO (1) WO2011050353A1 (US20080242721A1-20081002-C00053.png)
ZA (1) ZA201202557B (US20080242721A1-20081002-C00053.png)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201291460A1 (ru) 2010-05-28 2013-11-29 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Олигобензамидные соединения и их применение
WO2013023300A1 (en) * 2011-08-15 2013-02-21 The University Of British Columbia Inhibitors of androgen receptor activation function-2 (af2) as therapeutics and methods for their use
US9708276B2 (en) 2011-10-12 2017-07-18 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
US8835493B2 (en) 2011-11-23 2014-09-16 Board Of Regents, The University Of Texas System Oligo-benzamide compounds for use in treating cancers
US8754124B2 (en) 2011-11-23 2014-06-17 Board Of Regents, The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
JP6138928B2 (ja) 2012-06-01 2017-05-31 ライプニッツ−インスティテュート フュア アルテルスフォルシュング−フリッツ−リップマン−インスティテュート エー.ファウ.(エフエルイー) 医薬に使用されるnotchシグナル伝達経路及び分泌の阻害物質
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
EP3733170A1 (en) * 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
CN110845626A (zh) * 2012-07-27 2020-02-28 阿拉贡药品公司 用于确定抵抗雄激素受体疗法的方法和组合物
US20160024083A1 (en) * 2013-03-14 2016-01-28 Health Research, Inc. Compounds and methods for treating cancers
WO2015042297A1 (en) * 2013-09-20 2015-03-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compounds for treating prostate can cancer
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
ES2900149T3 (es) * 2016-07-21 2022-03-16 Hadasit Med Res Service Combinaciones que comprenden antagonistas o inhibidores de AR para su uso en el tratamiento del glioblastoma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224326A (en) * 1978-09-21 1980-09-23 Eli Lilly And Company Immunosuppressive agents
AU626881B2 (en) 1988-07-14 1992-08-13 F. Hoffmann-La Roche Ag Benzofused heterocyclics used as pharmaceuticals
AU3846395A (en) 1994-11-07 1996-05-31 Janssen Pharmaceutica N.V. Compositions comprising carbazoles and cyclodextrins
WO2005090282A1 (en) * 2004-03-12 2005-09-29 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
KR20060130781A (ko) * 2004-04-08 2006-12-19 토포타겟 에이/에스 다이페닐 인돌-2-온 화합물 및 암 치료에 있어서의 그의용도
US20060003966A1 (en) * 2004-06-16 2006-01-05 Jack Arbiser Carbazole formulations for the treatment of psoriasis and angiogenesis
GB0513702D0 (en) * 2005-07-04 2005-08-10 Sterix Ltd Compound
JP2009528383A (ja) * 2006-03-02 2009-08-06 スミスクライン・ビーチャム・コーポレイション Pi3キナーゼ阻害剤として用いるためのチアゾロン
WO2008051523A2 (en) * 2006-10-23 2008-05-02 Georgetown University Carbazole derivatives useful as medicaments in cancer therapy

Similar Documents

Publication Publication Date Title
JP2013508417A5 (US20080242721A1-20081002-C00053.png)
JP2014530861A5 (US20080242721A1-20081002-C00053.png)
MY160399A (en) Compounds, compositions, and methods for preventing metastasis of cancer cells
JP2010519270A5 (US20080242721A1-20081002-C00053.png)
JP2011088902A5 (US20080242721A1-20081002-C00053.png)
JP2014508752A5 (US20080242721A1-20081002-C00053.png)
JP2015512943A5 (US20080242721A1-20081002-C00053.png)
JP2012144574A5 (US20080242721A1-20081002-C00053.png)
EA201290208A1 (ru) Способ лечения андроген-рецептор позитивных раковых заболеваний
JP2011006405A5 (ja) 化合物
JP2012140436A5 (ja) 物質
EA201070477A1 (ru) Транс-кломифен для лечения метаболического синдрома
WO2011056021A3 (ko) 벤조헤테로사이클 유도체의 암 예방 및 치료 또는 암 전이 억제를 위한 용도
EP2620432A3 (en) Diarylhydantoin compounds
NZ603155A (en) Phospholipid drug analogs
NZ718514A (en) Compounds, compositions and methods useful for cholesterol mobilisation
JP2013063963A5 (ja) 複素環化合物
WO2007124345A3 (en) Beta-amyloid pet imaging agents
MY164086A (en) Novel antitumoral use of cabazitaxel
JP2013539778A5 (US20080242721A1-20081002-C00053.png)
JP2008509939A5 (US20080242721A1-20081002-C00053.png)
JP2014043437A5 (ja) 有機化合物
JP2013537240A5 (US20080242721A1-20081002-C00053.png)
JP2011508779A5 (US20080242721A1-20081002-C00053.png)
JP2012521353A5 (US20080242721A1-20081002-C00053.png)